Added to YB: 2025-04-09
Pitch date: 2025-04-07
GERN [bullish]
Geron Corporation
-4.9%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
Market Cap
$715.0M
Pitch Price
$1.43
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.80
P/E
-9.32
EV/Sales
2.28
Sector
Biotechnology
Category
growth
Show full summary:
ClearBridge Small Cap Growth Strategy New Position: Geron Corporation
GERN (new position): Biotech with newly commercialized blood cancer drug. Broad applicability across treatment cycles suggests larger revenue potential than market currently appreciates. Entering sizable market with growth opportunity.
Read full article (1 min)